User

The Effect of Recombinant Vascular Endothelial Growth Factor (VEGF)-121 Towards Placenta Growth Factor Serum Levels in Female Mice (Mus Musculus) with Preeclampsia Model

Wisnu Prabowo

Abstract

Background: Preeclampsia is a multi syste­mic disease which recognized by the develop­ment of hypertension after 20 weeks of gesta­tion with the presence of proteinuria or any signs indicative of target organ injury. The correct diagnosis and classification of the disease are essential since the therapies are unique in each class. Moreover, the angiogenic factors claims to play a significant role in the endothelial injury which plays as an etiology for preeclampsia. Thus, this study aimed to analyze the differences between angiogenic factors in pregnancy mice with preeclampsia models after administration of VEGF-121.

Subjects and Method: Subject of the study were swiss’s strains of pregnancy mice (Mus musculus) which divided into three groups that consist of 10 subject of study in each group. Subjects for this research were recruited between March and May 2015 in Biomedical Laboratory of The Faculty of Veterinary Medicine, Universitas Airlangga as part of a cross sectional study designed for analytical experimental. The angiogenic factor which measured was PIGF serum levels with ELISA method and only group of pregnant mice with preeclampsia model which administred with injection of VEGF-121.

Results: This study was conducted of 30 male and 30 female Mus musculus with homoge­neous characteristic in terms of age, average body weight and have never been pregnant before. The differences in PIGF serum levels between three observed group are significant (p=0.035).

Conclusion: Administration of VEGF-121 increased the PlGF serum levels in pregnant mice with preeclampsia model. Thus, the admi­nistration of VEGF-121 improves the condition of endothelial damage in preeclampsia with an increase in PlGF levels.

Keywords: angiogenic factors, preeclampsia, placenta growth factor, VEGF-121. 

Correspondence: Wisnu Prabowo. Department of Obstetrics and Gynecology, Dr. Moewardi Hospital. Kolonel Sutarto 132, Jebres, Surakarta, Central Java, Indonesia. Email: wisnuprabowofetomaternal­@gmail.com. Mobile: +6281390015151.

Journal of Maternal and Child Health (2021), 06(03): 307-313
https://doi.org/10.26911/thejmch.2021.06.03.08

Full Text:

PDF

References

Ananth K, Bdolah Y, et al. (2004). Angiogenic Imbalance in the Pathophysiology of Preeclampsia: Newer Insights. Semin Nephrol. 24: 548–556.


Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, et al. (2005). Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of preeclampsia. J Matern Fetal Neonatal Med. 17(1):3–18. https://doi.org/10.1080/14767050400028816.


Chen and Novel (2009).Angiogenic Factors for Predicting Preeclampsia: sFlt-1, PlGF, and Soluble Endoglin. Clinical Chemistry Journal. 2: 1-6.


Comiskey M, Warner C, Schust D (2006). MHC molecules of the preimplantation embryo and trophoblast. Immunology of pregnancy. 16:130-142. https://www.ncbi.nlm.nih.gov/books/NBK6277/.


Creasy R (2014). Maternal Fetal Medicine, Principle and Practice.7:756.


Cuningham (2013). William Obstetric. Twenty fifth Edition. MD: Lippincot Williams; Wilkins. 762-763.


Gilbert J., et al. (2010). Recombinant Vascular Endothelial Growth Factor 121 Infusion Lowers Blood Pressure and Improves Renal Function in Rats With Placental Ischemia-Induced Hypertension. Hypertension. 55:380-385.


Hagmann H, Thadhani R, Benzing T, Karu-manchi SA, Stepan H (2012). The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem. 58(5): 837-45. https://doi.org/10.1373/clinchem.2011.169094.


Herse F, Verlohren S, Wenzel K, Pape J, Muller DN, Modrow S, Wallukat G, Luft FC, et al. (2009). Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age−matched

case study. Hypertension. 53(2): 393-398. https://doi.org/10.1161/hypertensionaha.108.124115.


Holston A, Qian C, Yu KF, Epstein FH, Karumanchi SA, Levine RJ (2009). Circulating angiogenic factors in ges-tational proteinuria without hyperten-sion. Am J Obstet Gynecol. 200(4): 390–392. https://doi.org/10.1016/j.ajog.2008.10.033.


Karumanchi SA, Bdolah Y (2004). Hypoxia and sFlt-1 in Preeclampsia: The “Chicken-and Egg” Question. Endo-crinology. 145(11): 4835–4837. https://doi.org/10.1210/en.2004-1028.


Karumanchi A, Karumanchi SA, Lafayette R (2007). Pathophysiology of the cli-nical manifestations of preeclampsia. Clin J Am Soc Nephrol. 2(3): 543-549. https://doi.org/10.2215/cjn.03761106


Karumanchi A, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, et al. (2008). A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 21(1): 9-23. https://doi.org/10.1080/1476705-0701830480.


Levine R, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, et al. (2004). Circulating angiogenic factor and the risk of preeclampsia. N Engl J Med. 350(7): 672-683. https://doi.org/10.1056/nejmoa031884.


Levine R, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, et al. (2006). Soluble endoglin and other circulating antiangiogenic fac-tors in preeclampsia. N Engl J Med. 355(10): 992-1005. https://doi.org/-10.1056/nejmoa055352.


Li Z, Zhang Y, Ma JY, Kapoun AM, Shao Q, Kerr I, Lam A, et al. (2007). Recom-binant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension. 50(4): 686-692. https://doi.org/10.1-161/hypertensionaha.107.092098.


Poon LC, Nicolaides KH (2014). Early prediction of preeclampsia. Obstet Gynecol Int. 2014: 297397. https://dx.doi.org/10.1155%2F2014%2F297397.


Perkin E, et al. (2011). First trimester prediction of preeclampsia. Delfia Express PlGF Assay. 11:120


Shah DM (2007). Preeclampsia: new in-sight, Curr Opin Nephrol Hypertens. 16(3): 213-20. https://doi.org/10.10-97/mnh.0b013e3280d942e9.


Siddiqui A, Irani RA, Zhang Y, Dai Y, Blackwell SC, Ramin SM, Kellems RE, Xia Y (2011). Recombinant vasculer endothelial growth factor 121 attenueates autoantibody induced feature of preeclampsia in pregnant mice. Am J Hypertens. 24(5): 606-12. https://doi.org/10.1038/ajh.2010.247.


Sulistyowati S, Abadi A, Hood J, Soetjipto (2010). The influence of low HLA-G protein expression on HSP-70 and VCAM-1 profile in preeclampsia. Indones J Obstet Gynecol. 34(4): 185-190. http://inajog.com/index.php/journal/article/view/301/290.


Wang A, Rana S, Karumanchi SA (2009). Preeclampsia: The role of angiogenic factor in its pathogenesis. Am Physiol. 24: 147-15. https://doi.org/10.1152/physiol.00043.2008.

Refbacks

  • There are currently no refbacks.